Opinion

Video

Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC

Gary D. Steinberg, MD, discusses the unmet needs and current standard of care for patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC).

  1. What are some of the unmet needs in the treatment of non-muscle-invasive bladder cancer (NMIBC)?
  • Patients with intermediate and high risk NMIBC
  • Disease burden/effects on QoL

2. What is the current standard of care for patients with intermediate-risk or high risk NMIBC?

  • Surgical resection
  • Discuss shortage of BCG
Related Videos
Timothy Lyon, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Medcast series
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
1 expert is featured in this series.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma
January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke
"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options
January 17th 2025

Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options

Fed Ghali, MD
“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
New Drug Application initiated with FDA for TAR-200 for NMIBC
January 15th 2025

New Drug Application initiated with FDA for TAR-200 for NMIBC

Hannah Clarke Benjamin P. Saylor Kyle Doherty
The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial
January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke
“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.
© 2025 MJH Life Sciences

All rights reserved.